Does Missouri Medicaid cover Ozempic or Wegovy or Rybelsus for weight loss?

Covered, prior authorization. Wegovy is the non-preferred agent on the obesity GLP-1 PDL. Prior authorization for members 12 and over with a BMI of 30 or more, or a BMI of 27 or more with a weight-related comorbidity, or MASH with F2/F3 fibrosis

Does Missouri Medicaid cover Mounjaro or Zepbound for weight loss?

Covered, prior authorization. Zepbound is the preferred agent on the obesity GLP-1 PDL. Prior authorization for members 12 and over meeting the BMI or MASH criteria

Does Missouri Medicaid cover Saxenda or Victoza for weight loss?

Not covered. Saxenda is not on the obesity GLP-1 PDL. The policy says anti-obesity medications not listed in it remain excluded from coverage

Medicaid coverage

Missouri: what Medicaid covers

Missouri’s MO HealthNet began covering select GLP-1 weight-loss drugs for members aged 12 and older. Zepbound is the preferred agent and Wegovy is covered as a non-preferred drug with prior authorization, both requiring a BMI of 30 or more, or a BMI of 27 or more with a weight-related condition, or MASH. Saxenda is not on the list, and the state’s own policy says anti-obesity drugs not listed remain excluded.

Checked against the primary source August 27, 2026

What Medicaid in Missouri covers, and the criteria that apply.
Drug	Position	Criteria
Semaglutide	Prior authorization	Wegovy is the non-preferred agent on the obesity GLP-1 PDL. Prior authorization for members 12 and over with a BMI of 30 or more, or a BMI of 27 or more with a weight-related comorbidity, or MASH with F2/F3 fibrosis Changed April 23, 2026
Tirzepatide	Prior authorization	Zepbound is the preferred agent on the obesity GLP-1 PDL. Prior authorization for members 12 and over meeting the BMI or MASH criteria Changed April 23, 2026
Liraglutide	Not covered	Saxenda is not on the obesity GLP-1 PDL. The policy says anti-obesity medications not listed in it remain excluded from coverage Changed April 23, 2026

Semaglutide Prior authorization

Wegovy is the non-preferred agent on the obesity GLP-1 PDL. Prior authorization for members 12 and over with a BMI of 30 or more, or a BMI of 27 or more with a weight-related comorbidity, or MASH with F2/F3 fibrosis

Changed April 23, 2026
Tirzepatide Prior authorization

Zepbound is the preferred agent on the obesity GLP-1 PDL. Prior authorization for members 12 and over meeting the BMI or MASH criteria

Changed April 23, 2026
Liraglutide Not covered

Saxenda is not on the obesity GLP-1 PDL. The policy says anti-obesity medications not listed in it remain excluded from coverage

Changed April 23, 2026

If the answer is no. Around 45% of initial prior authorizations for these drugs are refused, and 35 to 45% of first-level appeals are overturned. A refusal is not the end of the process, and the cash-pay routes are priced on this site alongside it.

Sources

Every claim above is checked against the primary text, and the date is the day we last opened it.

1
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Indicated for Obesity PDL Edit (SmartPA Criteria Proposal, revised April 23, 2026)
Missouri Department of Social Services, MO HealthNet Division Primary text read and checked Checked August 27, 2026